Search

Your search keyword '"Aden, Tilman"' showing total 6 results
Start Over Author "Aden, Tilman" Publication Year Range Last 3 years
6 results on '"Aden, Tilman"'

1. Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial

Author

Pinazo, Maria-Jesus, Forsyth, Colin, Losada, Irene, Esteban, Elena Trigo, García-Rodríguez, Magdalena, Villegas, Maria Luz, Molina, Israel, Crespillo-Andújar, Clara, Gállego, Montserrat, Ballart, Cristina, Ramirez, Juan Carlos, Aden, Tilman, Hoerauf, Achim, Pfarr, Kenneth, Vaillant, Michel, Marques, Tayná, Fernandes, Jayme, Blum, Bethania, Ribeiro, Isabela, Sosa-Estani, Sergio, Barreira, Fabiana, and Gascón, Joaquim

Published
2024
Full Text
View/download PDF

2. Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus

Author

Rox, Katharina, primary, Becker, Tim, additional, Schiefer, Andrea, additional, Grosse, Miriam, additional, Ehrens, Alexandra, additional, Jansen, Rolf, additional, Aden, Tilman, additional, Kehraus, Stefan, additional, König, Gabriele M., additional, Krome, Anna K., additional, Hübner, Marc P., additional, Wagner, Karl G., additional, Stadler, Marc, additional, Pfarr, Kenneth, additional, and Hoerauf, Achim, additional

Published
2022
Full Text
View/download PDF

3. Pharmacology and early ADMET data of corallopyronin A, a natural product with macrofilaricidal anti-wolbachial activity in filarial nematodes

Author

Ehrens, Alexandra, primary, Schiefer, Andrea, additional, Krome, Anna K., additional, Becker, Tim, additional, Rox, Katharina, additional, Neufeld, Helene, additional, Aden, Tilman, additional, Wagner, Karl G., additional, Müller, Rolf, additional, Grosse, Miriam, additional, Stadler, Marc, additional, König, Gabriele M., additional, Kehraus, Stefan, additional, Alt, Silke, additional, Hesterkamp, Thomas, additional, Hübner, Marc Peter, additional, Pfarr, Kenneth, additional, and Hoerauf, Achim, additional

Published
2022
Full Text
View/download PDF

4. In Vitro–In Vivo Relationship in Mini-Scale—Enabling Formulations of Corallopyronin A

Author

Becker, Tim, primary, Krome, Anna K., additional, Vahdati, Sahel, additional, Schiefer, Andrea, additional, Pfarr, Kenneth, additional, Ehrens, Alexandra, additional, Aden, Tilman, additional, Grosse, Miriam, additional, Jansen, Rolf, additional, Alt, Silke, additional, Hesterkamp, Thomas, additional, Stadler, Marc, additional, Hübner, Marc P., additional, Kehraus, Stefan, additional, König, Gabriele M., additional, Hoerauf, Achim, additional, and Wagner, Karl G., additional

Published
2022
Full Text
View/download PDF

5. The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus

Author

Balansky, Jan, primary, Pfarr, Kenneth, additional, Szekat, Christiane, additional, Kehraus, Stefan, additional, Aden, Tilman, additional, Grosse, Miriam, additional, Jansen, Rolf, additional, Hesterkamp, Thomas, additional, Schiefer, Andrea, additional, König, Gabriele M., additional, Stadler, Marc, additional, Hoerauf, Achim, additional, and Bierbaum, Gabriele, additional

Published
2022
Full Text
View/download PDF

6. Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus.

Author

Rox, Katharina, Becker, Tim, Schiefer, Andrea, Grosse, Miriam, Ehrens, Alexandra, Jansen, Rolf, Aden, Tilman, Kehraus, Stefan, König, Gabriele M., Krome, Anna K., Hübner, Marc P., Wagner, Karl G., Stadler, Marc, Pfarr, Kenneth, and Hoerauf, Achim

Subjects
METHICILLIN-resistant staphylococcus aureus, PHARMACODYNAMICS, PHARMACOKINETICS, FEMUR, LUNGS, NATURAL products
Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a World Health Organization's high priority pathogen organism, with an estimated > 100,000 deaths worldwide in 2019. Thus, there is an unmet medical need for novel and resistance-breaking anti-infectives. The natural product Co-rallopyronin A (CorA), currently in preclinical development for filariasis, is efficacious against MRSA in vitro. In this study, we evaluated the pharmacokinetics of CorA after dosing in mice. Furthermore, we determined compound concentrations in target compartments, such as lung, kidney and thigh tissue, using LC-MS/MS. Based on the pharmacokinetic results, we evaluated the pharmacodynamic profile of CorA using the standard neutropenic thigh and lung infection models. We demonstrate that CorA is effective in both standard pharmacodynamic models. In addition to reaching effective levels in the lung and muscle, CorA was detected at high levels in the thigh bone. The data presented herein encourage the further exploration of the additional CorA indications treatment of MRSA- and methicillin-sensitive S. aureus- (MSSA) related infections. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results